Related Experiment Video
Updated: Jan 29, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Porous Polymeric Microparticles as an Oral Drug Platform for Effective Ulcerative Colitis Treatment
Xin Zhou1, Qiubing Chen1, Ya Ma1
1Education Ministry Key Laboratory on Luminescence and Real-Time Analysis, Institute for Clean Energy and Advanced Materials, School of Materials and Energy, Southwest University, Beibei, Chongqing 400715, P.R. China.
Porous microparticles enhance curcumin drug delivery, showing superior therapeutic effects for ulcerative colitis treatment in mice compared to nonporous versions. This highlights porous microparticles as a promising oral drug delivery platform.
Area of Science:
- Materials Science
- Nanotechnology
- Pharmacology
Background:
- Microparticles (MPs) are explored for drug delivery.
- Porous MPs offer potential advantages over nonporous MPs.
- Curcumin is a therapeutic agent with potential for ulcerative colitis treatment.
Purpose of the Study:
- To compare the efficacy of porous and nonporous microparticles for curcumin encapsulation and delivery.
- To evaluate the therapeutic potential of these microparticles in a ulcerative colitis mouse model.
Main Methods:
- Porous and nonporous MPs were fabricated using emulsion-solvent evaporation.
- Curcumin was encapsulated into MPs during preparation.
- MP characteristics (size, zeta potential) were analyzed.
- Curcumin release kinetics were studied.
- Ulcerative colitis was induced in mice using dextran sulfate sodium.
Main Results:
- MPs with and without pores were successfully prepared with ~1.2 μm diameters and negative zeta potentials (~-28 mV).
- Porous MPs demonstrated a significantly increased curcumin release rate.
- Orally administered porous MPs yielded statistically significant improvements in treating ulcerative colitis in mice compared to nonporous MPs.
Conclusions:
- Porous microparticles significantly enhance curcumin release and therapeutic efficacy for ulcerative colitis.
- Porous MPs represent a promising platform for oral drug delivery in ulcerative colitis treatment.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Non-Oral Extravascular Drug Absorption Routes
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

